Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T
Children's Hospital, University of Helsinki, Finland.
J Clin Immunol. 1988 Mar;8(2):89-94. doi: 10.1007/BF00917895.
A nationwide vaccination campaign with oral poliovirus vaccine was organized in Finland in 1985 in order to cease an outbreak of poliomyelitis. We followed eight IgA-deficient individuals and nine controls for poliovirus excretion in feces and for antibody responses in serum and saliva. Five weeks after oral poliovirus vaccination all eight IgA-deficient individuals were still excreting polioviruses, in contrast to one of nine controls. The concentration of polioviruses, as estimated by a semi-quantitative immunofluorescent assay, was generally higher and the test was significantly more often positive in the samples from the IgA-deficient individuals. Although serum levels of antibodies to poliovirus type 3 were lower in IgA-deficient individuals before vaccination, both measurements showed that the two groups had similar antibody levels 4 weeks after vaccination. IgA-deficient individuals lacked salivary IgA antibodies to poliovirus types 1 and 3 but had increased levels of IgM antipolio antibodies, which were shown to carry secretory component. We conclude that the mucosal IgM antibodies of IgA-deficient individuals eliminate polioviruses less efficiently than do the IgA antibodies of normal individuals.
1985年,芬兰组织了一场全国性的口服脊髓灰质炎疫苗接种运动,以遏制脊髓灰质炎的爆发。我们对8名IgA缺陷个体和9名对照者进行了跟踪,检测他们粪便中的脊髓灰质炎病毒排泄情况以及血清和唾液中的抗体反应。口服脊髓灰质炎疫苗接种五周后,所有8名IgA缺陷个体仍在排泄脊髓灰质炎病毒,而9名对照者中只有1人仍在排泄。通过半定量免疫荧光测定法估计,IgA缺陷个体样本中脊髓灰质炎病毒的浓度通常更高,检测呈阳性的频率也明显更高。虽然在接种疫苗前,IgA缺陷个体中针对脊髓灰质炎3型的抗体血清水平较低,但两项检测均显示,两组在接种疫苗4周后的抗体水平相似。IgA缺陷个体缺乏针对脊髓灰质炎1型和3型的唾液IgA抗体,但IgM抗脊髓灰质炎抗体水平升高,且这些抗体带有分泌成分。我们得出结论,IgA缺陷个体的黏膜IgM抗体清除脊髓灰质炎病毒的效率低于正常个体的IgA抗体。